National Cancer Institute - NCI Division of Cancer Treatment and ...
National Cancer Institute - NCI Division of Cancer Treatment and ... National Cancer Institute - NCI Division of Cancer Treatment and ...
■ In vivo animal model results for 30,000 compounds ■ 2-D and 3-D chemical structures for more than 200,000 compounds ■ Molecular target data, including characterizations for at least 1200 targets, plus data from multiple cDNA microarray projects In addition to browsing DTP’s databases and downloading data, researchers can request individual samples or sets of compounds on 96-well plates for research, or they can submit their own compounds for consideration for screening via DTP’s online submission form. Once a compound is submitted for screening, researchers can follow its progress and retrieve data using a secure Web interface. The NCI has collected information on almost half a million chemical structures in the past 40 years. DTP has made this information accessible and useful for investigators through its 3-D database, a collection of three-dimensional structures for more than 400,000 drugs. Investigators use the 3-D database, which is maintained by DTP, to screen compounds for anticancer therapeutic activity. Also available on DTP’s Website are 127,000 connection tables for anticancer agents. A connection table is a convenient way of depicting molecular structures without relying on drawn chemical structures. As unique lists of atoms and their connections, the connection tables can be indexed and stored in computer databases where they can be used for patent searches, toxicology studies, and precursor searching, for example. Courtesy of Essential Eye Photographics. The Website and its databases are maintained by the Information Technology Branch. Drug Development Biological Resources Branch Preclinical Repository http://web.ncifcrf.gov/research/brb/ site/preclinRepo.asp This repository, an NCI-sponsored facility, stores bulk cytokines, monoclonal antibodies, and cytokine standards under carefully controlled conditions. The repository provides a constant and uniform supply of high-quality reagents to nonprofit institutions and qualified D E V E L O P M E N T A L T H E R A P E U T I C S P R O G R A M ■ 109
National Cancer Institute. commercial establishments at no charge. This facility obtains new materials by donation or at reduced cost by negotiating with companies and investors. To date, the Biological Resources Branch Preclinical Repository has distributed more than 40,000 samples, and the estimated value of materials shipped to investigators is about $100,000 per year. Radiolabeled Materials Repository http://dtp.nci.nih.gov/docs/misc/ available_samples/radiolbllist2.html For researchers who hold a valid radioactive materials license, there are roughly 90 radiolabeled drugs available from DTP’s Radiolabeled Materials Repository. Radiolabeled compounds are instrumental in noninvasive studies of biodistribution and in target pharmacokinetics of therapeutics. In early trials, 11 of 16 patients with hairy cell leukemia had complete remissions after receiving BL22. 110 ■ P R O G R A M A C C O M P L I S H M E N T S 2 0 0 6 Drug Formulation and Synthesis DTP’s Pharmaceutical Resources Branch bears the responsibility of acquiring bulk materials for formulation and synthesis, formulating drugs and testing them, clinical dosage-form production, and stability testing of clinical dosage forms. This branch provides clinical researchers, both academic and institutional, with topquality drugs for clinical trials and formulates drug compounds that are candidates for the Drug Development Group or the RAID program. Drug Production: Biopharmaceutical Development Program http://wwwbdp.ncifcrf.gov/ DTP’s Biological Resources Branch oversees the Biopharmaceutical Development Program (BDP), which provides biopharmaceutical development expertise and production capability to all NIH-supported investigators. The BDP produces a variety of clinical-grade biological agents from bacterial, yeast, and mammalian cells; natural products from various organisms; and DNA, RNA, and viral materials under current Good Manufacturing Practices for phase I/II human clinical trials or advanced preclinical animal testing. Researchers have attempted to design cancer therapies to avoid toxicities associated with standard chemotherapeutic agents. BL22, one such targeted treatment, originated in an intramural NCI laboratory and was developed through DTP’s biologicals production facility.
- Page 63 and 64: Association of American Cancer Inst
- Page 65 and 66: Food and Drug Administration and Ce
- Page 67 and 68: Dr. Edward A. Neuwelt, Oregon Healt
- Page 69 and 70: Virtual Colonoscopy Training Collec
- Page 71 and 72: Not only does CTEP identify promisi
- Page 73 and 74: The Clinical Trials Cooperative Gro
- Page 75 and 76: of pediatric cancers and therapeuti
- Page 77 and 78: the front line treatment of chronic
- Page 79 and 80: Quick-Trials for Novel Cancer Thera
- Page 81 and 82: Industry Collaborators Agent Name 7
- Page 83 and 84: Industry Collaborators Agent Name 7
- Page 85 and 86: NCI Visuals Online, George McGregor
- Page 87 and 88: provided for use in this clinical t
- Page 89 and 90: with or without bevacizumab (NSC #
- Page 91 and 92: Oxaliplatin-Based Regimen Permits S
- Page 93 and 94: egular checkups to look for lymph-n
- Page 95 and 96: NCI Visuals Online. Human lymphoma
- Page 97 and 98: T O O L S , P R O D U C T S , A N D
- Page 99 and 100: ■ Clinical Trials Monitoring Bran
- Page 101 and 102: DTP’s staff and administered gran
- Page 103 and 104: therapeutics. Proposed exploratory
- Page 105 and 106: M A J O R O N G O I N G I N I T I A
- Page 107 and 108: National Cancer Institute. discover
- Page 109 and 110: C U R R E N T F U N D I N G O P P O
- Page 111 and 112: DTP oversees animal-production faci
- Page 113: disease can require considerable in
- Page 117 and 118: The Type 1 Diabetes Rapid Access to
- Page 119 and 120: H I S T O R Y - M A R K I N G E V E
- Page 121 and 122: With this approach, patients are no
- Page 123 and 124: This included a camptothecin deriva
- Page 125 and 126: RRP supports research involving a v
- Page 127 and 128: Laredo Medical Center, Laredo, TX h
- Page 129 and 130: With TELESYNERGY® as a link, healt
- Page 131 and 132: Radiation Bioterrorism Research and
- Page 133 and 134: Enhanced Radiosensitivity The Molec
- Page 135 and 136: M E E T I N G S A N D W O R K S H O
- Page 137 and 138: Cancer Imaging Program 132 ■ P R
- Page 139 and 140: Cancer Therapy Evaluation Program,
- Page 141 and 142: Developmental Therapeutics Program,
- Page 143 and 144: Developmental Therapeutics Program,
■ In vivo animal model results for 30,000<br />
compounds<br />
■ 2-D <strong>and</strong> 3-D chemical structures for<br />
more than 200,000 compounds<br />
■ Molecular target data, including<br />
characterizations for at least 1200<br />
targets, plus data from multiple cDNA<br />
microarray projects<br />
In addition to browsing DTP’s databases<br />
<strong>and</strong> downloading data, researchers can<br />
request individual samples or sets <strong>of</strong><br />
compounds on 96-well plates for research,<br />
or they can submit their own compounds<br />
for consideration for screening<br />
via DTP’s online submission form. Once<br />
a compound is submitted for screening,<br />
researchers can follow its progress <strong>and</strong><br />
retrieve data using a secure Web interface.<br />
The <strong>NCI</strong> has collected information on<br />
almost half a million chemical structures<br />
in the past 40 years. DTP has made this<br />
information accessible <strong>and</strong> useful for<br />
investigators through its 3-D database, a<br />
collection <strong>of</strong> three-dimensional structures<br />
for more than 400,000 drugs. Investigators<br />
use the 3-D database, which is maintained<br />
by DTP, to screen compounds for anticancer<br />
therapeutic activity.<br />
Also available on DTP’s Website are<br />
127,000 connection tables for anticancer<br />
agents. A connection table is a convenient<br />
way <strong>of</strong> depicting molecular structures<br />
without relying on drawn chemical structures.<br />
As unique lists <strong>of</strong> atoms <strong>and</strong> their<br />
connections, the connection tables can<br />
be indexed <strong>and</strong> stored in computer databases<br />
where they can be used for patent<br />
searches, toxicology studies, <strong>and</strong> precursor<br />
searching, for example.<br />
Courtesy <strong>of</strong> Essential Eye Photographics.<br />
The Website <strong>and</strong> its databases are maintained<br />
by the Information Technology<br />
Branch.<br />
Drug Development<br />
Biological Resources Branch<br />
Preclinical Repository<br />
http://web.ncifcrf.gov/research/brb/<br />
site/preclinRepo.asp<br />
This repository, an <strong>NCI</strong>-sponsored facility,<br />
stores bulk cytokines, monoclonal<br />
antibodies, <strong>and</strong> cytokine st<strong>and</strong>ards under<br />
carefully controlled conditions. The repository<br />
provides a constant <strong>and</strong> uniform<br />
supply <strong>of</strong> high-quality reagents to<br />
nonpr<strong>of</strong>it institutions <strong>and</strong> qualified<br />
D E V E L O P M E N T A L T H E R A P E U T I C S P R O G R A M ■ 109
Change language